Italia markets close in 2 hours 14 minutes
FTSE MIB
33.821,84 +75,18 (+0,22%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,04 +0,04 (+0,05%) Bitcoin EUR
54.719,64 +659,17 (+1,22%)
NovoCure Limited (NVCR)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Preborsa:
| Chiusura precedente | 12,24 |
| Aperto | 12,24 |
| Denaro | 12,70 x 800 |
| Lettera | 12,77 x 1700 |
| Min-Max giorno | 12,24 - 13,26 |
| Intervallo di 52 settimane | 10,87 - 83,60 |
| Volume | |
| Media Volume | 1.289.957 |
| Capitalizzazione | 1,371B |
| Beta (5 anni mensile) | 0,43 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,95 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 27,33 |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.